Compare LODE & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LODE | ANTX |
|---|---|---|
| Founded | 1999 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 161.9M | 172.9M |
| IPO Year | 2004 | 2022 |
| Metric | LODE | ANTX |
|---|---|---|
| Price | $1.80 | $3.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | ★ 1.4M | 315.3K |
| Earning Date | 10-29-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.55 | 32.56 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,553,796.00 | N/A |
| Revenue This Year | $303.79 | N/A |
| Revenue Next Year | $410.04 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.84 | $1.00 |
| 52 Week High | $4.98 | $7.19 |
| Indicator | LODE | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | 17.73 | 24.35 |
| Support Level | N/A | $2.87 |
| Resistance Level | $3.32 | $5.21 |
| Average True Range (ATR) | 0.12 | 0.43 |
| MACD | -0.02 | -0.17 |
| Stochastic Oscillator | 4.82 | 9.40 |
Comstock Inc commercializes technologies that convert underutilized waste and natural resources into clean energy and supporting products, including electrification, metals, and minerals from end-of-life solar panels. Its subsidiary focuses on producing renewable fuels from waste, energy crops, and woody biomass, supported by facilities in Wisconsin, pilot farms, a biorefinery site in Tulsa, and solar panel recycling operations in Nevada. The Company operates through two high-growth segments and a corporate segment, with its activities grouped into Metals, which generates the majority of revenue, Fuels, Mining, Strategic Investments, and Corporate Services.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.